Dr Mark Fendrick, PAN Foundation's Dan Klein Commend Trump Administration's Drug Rebate Proposal

SAP Partners | <b>PAN Foundation</b>

In a commentary, Dan Klein, president and chief operating officer of the Patient Access Network Foundation, and A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design at the University of Michigan, called the Trump administration's recent drug rebate proposal an opportunity to significantly lower out-of-pocket precription drug costs for Medicare patients.

In a commentary, Dan Klein, president and chief operating officer of the Patient Access Network Foundation, and A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design at the University of Michigan, called the Trump administration's recent drug rebate proposal an opportunity to significantly lower out-of-pocket precription drug costs for Medicare patients. The pair called the proposal spot on for both improving access and affordability but note that accomplishing these goals will require support from all key stakeholders, including patient advocates, pharmaceutical companies, health plans, and pharmaceutical benefit managers.

However, they caution that, like most things in healthcare, there is more complexity to the proposal that initially meets the eye. Read more here.